President,
Certified Public Accountant
Yosuke Tochihara has extensive experience in various roles within pharmaceutical and biotechnology companies. In his previous position, he served as the Japan Representative for a biotechnology venture. He assumed the role of CEO of the company in October 2022.
1995
Graduated from Keio University, Faculty of Economics.
Pharmaceutical sales at Yamanouchi Pharmaceutical (now Astellas).
2001
Nippon Life Insurance Company.
2006
Arata Audit Corporation (currently PwC Audit Corporation).
2013
Deloitte Touche Tohmatsu LLC.
2019
Executive Director and Japan Representative at Elixirgen Therapeutics.
Director
After gaining experience in the treatment of acute and chronic cardiovascular diseases at a tertiary emergency hospital, Dr. Taniyama began basic research aimed at developing new treatments for heart failure. While working on a drug for heart failure, he conceived the idea of developing a drug for chemotherapy-resistant malignant tumors and founded a company to conduct clinical trials for the treatment of chemotherapy-resistant breast cancer.
1993
Graduated from Tohoku University School of Medicine
1994
Physician, Department of Cardiology, Sakurabashi Watanabe Hospital
2000-2001
Research Fellow in Molecular Cardiology, Tufts University/Boston University School of Medicine
2002
Research Assistant, Department of Clinical Gene Therapy/Aging Medicine, Osaka University School of Medicine
2007
Associate Professor, Department of Clinical Gene Therapy, Department of Geriatrics and General Medicine, Osaka University School of Medicine
2017
Founder and CEO of Periotherapy Inc.; Concurrently Visiting Professor at Osaka University
2022
Specially Appointed Professor, Department of Advanced Molecular Therapy, Osaka University School of Medicine
Director
After working at a university hospital and a city hospital starting in 2001, he began basic research in 2006 and has been engaged in periostin research for about 10 years. He has been involved in the venture since its inception and is primarily responsible for the basic research aspect.
2000
Graduated from Niigata University School of Medicine
2005
Special Researcher, Osaka University School of Medicine
2008
Research Fellow, Harvard Medical School
2012
Assistant Professor, Department of Clinical Gene Therapy, Osaka University School of Medicine
2016
Associate Professor, Department of Clinical Gene Therapy, Osaka University School of Medicine
Director and COO
Utilizing my experience in basic research on cancer and aging at university and graduate school, I have been engaged in research and development, research management, and drug licensing negotiations in a wide range of fields, including drug discovery, diagnostics, and healthcare, at a domestic pharmaceutical company. At a biotech startup, I served as CEO, overseeing management, research and development, business development, fundraising, and IPO preparation, and have been in my current position since June 2025.
2001
Doctor of Pharmacy, Graduate School of Medicine, Hiroshima University
2001
Researcher, Research and Development Division, Wakunaga Pharmaceutical Co., Ltd.
2005
MD Anderson Cancer Center(U.S.) Visiting Scientist
2008
Associate Researcher, Drug Discovery Research Laboratory, Wakunaga Pharmaceutical Co., Ltd.
2009
Wakunaga of America, R&D Manager
2013
MiRTeL Co.LTD. President and CEO
2022
Senior Manager, Principal, Research Management Department, Wakunaga Pharmaceutical Co., Ltd.
Director (Outside the Company)
Director of the Investment Division, Osaka University Venture Capital Co., Ltd.
Director (Outside the Company)
Deputy General Manager, Life Sciences Department, Mitsubishi UFJ Capital Co., Ltd.
Audit & Supervisory Board Member (Outside the Company)
Representative Director, Umegae Chuo Accounting Co., Ltd. / Certified Public Accountant
Executive Officer and CFO
After graduating from the University of Tokyo, he gained experience in various industries, including fundraising, cross-border M&A, business transfers, and negotiation, as well as project management skills in areas such as IPO preparation. He joined our company as CFO in May 2025.
1989
Graduated from the Department of Public Law, Faculty of Law, University of Tokyo
1989
ITOCHU Corporation, Textile Division Sales Representative
1993
Completed CEP course at Sciences Po Paris
2006
Broadband Division Manager, GDH Co., Ltd.
2009
ROSSO INDEX K.K. Executive Officer, President's Office Manager
2011
ZENRIN DataCom CO., LTD. Overseas Business Division Manager
2018
ZENRIN DataCom CO., LTD. Executive Officer, General Manager of Corporate Planning Division
2021
ZENRIN DataCom CO., LTD.Senior Executive Officer, General Manager of Corporate Planning Division
2024
CFO, EneCoat Technologies Co., Ltd.
Osaka University Venture Capital Co., Ltd.
Mitsubishi UFJ Capital Co., Ltd.
Chishima Real Estate Co., Ltd.
Technoscience Ltd.
Eisai Co., Ltd.
Chushin Venture Capital Co., Ltd.
